-
How We Define Success for a Clinical Trial
Read time: 6 minutes. This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are... -
Understanding Clinical Trials: Why Are They Important for Drug Development?
Read time: 3 minutes. This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming... -
HER2+ NSCLC: Understanding the Latest Treatment and Advances
Many people have heard of HER2-positive breast cancer. But HER2 is an important biomarker found in many different types of cancer—including non-small cell lung cancer (NSCLC). A... -
Countdown to ILCSC24: Bringing the World’s Experts Right to Your Living Room
Read time: 3 minutes. One of LUNGevity’s two flagship survivorship events, the International Lung Cancer Survivorship Conference (ILCSC), is being held virtually September 20 – 21... -
How Can Patients and Researchers Design Clinical Trials Together?
Read time: 2 minutes. Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with... -
2024 ASCO: Highlights of Lung Cancer Research
Read time: 8 minutes Thousands of oncologists, scientists, biotech and pharmaceutical representatives, patients, and advocates (including LUNGevity staff) met to discuss lifesaving... -
Repotrectinib Approvals Expand to Include Patients with NTRK+ Solid Tumors
On June 13, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of repotrectinib (Augtyro™) to treat patients with advanced NTRK-positive solid... -
Is Lung Cancer in Young Adults Hereditary?
Read time: 2 minutes The question of whether lung cancer is hereditary is becoming increasingly important in the lung cancer community. While the average age of lung cancer... -
Researcher Aims to Bring 360-Degree Care to Young Adults Living with Lung Cancer
Young adults (less than 50 years of age) are being diagnosed with lung cancer at increasing rates. They tend to be women of Hispanic or Asian descent and are typically diagnosed... -
Advice and Insights from Author and Two-Time Cancer Survivor Kathy Giusti
Kathy Giusti joined LUNGevity for a special conversation about her life as a cancer patient, caregiver, and the founder and former CEO of the Multiple Myeloma Research Foundation... -
Safely Bring Yoga, Dietary Supplements, Exercise, and More into Your Lung Cancer Journey
Read time: 2 minutes Integrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these... -
Kicking Drug Resistance to the Curb in RET-positive Lung Cancer
Read time: 4 minutes Lung cancers that test positive for the RET biomarker are often treated with targeted therapy. While this type of treatment has improved the duration and...
Rare Mutations and Fusions